The Latin America pharmaceutical contract manufacturing and research services market size was estimated at USD 20.2 billion in 2025 and is projected to reach USD 37.2 billion by 2033, growing at a CAGR of 8.1% from 2026 to 2033. The market is driven by cost efficiency, expanding clinical research capabilities, rising demand for outsourced services, and improving regulatory frameworks.
Some other factors contributing to market growth are the rising demand for generics & biosimilars, coupled with the growing need for local pharmaceutical production, which further drives the need for outsourcing services. In addition, investments from global pharmaceutical companies, improvements in healthcare infrastructure, and government initiatives are promoting domestic manufacturing and innovation. Besides, growing strategic partnerships and technological advancements are boosting regional competitiveness.
The increasing focus on cost efficiency has encouraged pharmaceutical companies to outsource biopharmaceutical production to specialized contract manufacturers. Besides, the expansion of the pharmaceutical and biologics industry, the rising prevalence of chronic diseases, the increasing healthcare expenditure, and the growing demand for affordable medicines are driving pharmaceutical companies to scale up production. Thus, growing outsourcing to contract manufacturers and research organizations is helping companies meet demand without heavy capital investment.
In addition, product innovation in the market is no longer confined to in-house R&D within large biopharma companies; instead, Latin America’s smaller and mid-sized biotech firms are playing a critical role in discovering novel molecules, which are often later acquired by established players. This shift has led contract research organizations (CROs) to increasingly secure partnerships and contracts with emerging biotech companies, ensuring sustained service demand and volume growth.
Moreover, strong government initiatives in Latin America aim to enhance domestic production and healthcare independence. Countries like Brazil and Mexico are actively supporting local biologics manufacturing through public funding, tax incentives, and technology transfer programs. In Brazil, government-supported partnerships under public healthcare policies have led to a significant increase in local biologics production, thereby reducing reliance on imports. Besides, regulatory bodies such as ANVISA have simplified approval processes, facilitating scaling of manufacturing operations. These policy-driven initiatives are strengthening regional capabilities, attracting investment, and driving growth in the pharmaceutical manufacturing sector across Latin America.
Furthermore, companies in the region are strengthening their global footprint by upgrading and expanding domestic specialty manufacturing facilities while actively pursuing international collaborations. The growing presence of market players such as Thermo Fisher Scientific and IQVIA in key countries, including Brazil, Mexico, Argentina, and Chile, is further accelerating market growth. In addition, supportive regulatory improvements, increasing clinical trial activity, and a growing skilled workforce are enhancing the region’s attractiveness as a hub for pharmaceutical development and outsourcing services.
Some other factors contributing to market growth are the rising demand for generics & biosimilars, coupled with the growing need for local pharmaceutical production, which further drives the need for outsourcing services. In addition, investments from global pharmaceutical companies, improvements in healthcare infrastructure, and government initiatives are promoting domestic manufacturing and innovation. Besides, growing strategic partnerships and technological advancements are boosting regional competitiveness.
The increasing focus on cost efficiency has encouraged pharmaceutical companies to outsource biopharmaceutical production to specialized contract manufacturers. Besides, the expansion of the pharmaceutical and biologics industry, the rising prevalence of chronic diseases, the increasing healthcare expenditure, and the growing demand for affordable medicines are driving pharmaceutical companies to scale up production. Thus, growing outsourcing to contract manufacturers and research organizations is helping companies meet demand without heavy capital investment.
In addition, product innovation in the market is no longer confined to in-house R&D within large biopharma companies; instead, Latin America’s smaller and mid-sized biotech firms are playing a critical role in discovering novel molecules, which are often later acquired by established players. This shift has led contract research organizations (CROs) to increasingly secure partnerships and contracts with emerging biotech companies, ensuring sustained service demand and volume growth.
Moreover, strong government initiatives in Latin America aim to enhance domestic production and healthcare independence. Countries like Brazil and Mexico are actively supporting local biologics manufacturing through public funding, tax incentives, and technology transfer programs. In Brazil, government-supported partnerships under public healthcare policies have led to a significant increase in local biologics production, thereby reducing reliance on imports. Besides, regulatory bodies such as ANVISA have simplified approval processes, facilitating scaling of manufacturing operations. These policy-driven initiatives are strengthening regional capabilities, attracting investment, and driving growth in the pharmaceutical manufacturing sector across Latin America.
Furthermore, companies in the region are strengthening their global footprint by upgrading and expanding domestic specialty manufacturing facilities while actively pursuing international collaborations. The growing presence of market players such as Thermo Fisher Scientific and IQVIA in key countries, including Brazil, Mexico, Argentina, and Chile, is further accelerating market growth. In addition, supportive regulatory improvements, increasing clinical trial activity, and a growing skilled workforce are enhancing the region’s attractiveness as a hub for pharmaceutical development and outsourcing services.
Latin America Pharmaceutical Contract Manufacturing & Research Services Market Report Segmentation
This report forecasts revenue growth at regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the Latin America pharmaceutical contract manufacturing & research services market report based on service and region.Service Outlook (Revenue, USD Million, 2021-2033)
- Manufacturing
- API/Bulk Drugs
- Advanced Drug Delivery Formulations
- Packaging
- Finished Dose Formulations
- Solid
- Liquid
- Semi-solid Formulations
- Research
- Oncology
- Vaccines
- Inflammation & Immunology
- Cardiology
- Neuroscience
- Others
Regional Outlook (Revenue, USD Million, 2021-2033)
- Latin America
- Brazil
- Colombia
- Argentina
- Chile
- Venezuela
- Peru
- Uruguay
- Ecuador
- Bolivia
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Table of Contents
Chapter 1. Research Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Latin America Pharmaceutical Contract Manufacturing & Research Services Market Variables, Trends & Scope
Chapter 4. Latin America Pharmaceutical Contract Manufacturing & Research Services Market: Product Estimates & Trend Analysis
Chapter 5. Latin America Pharmaceutical Contract Manufacturing & Research Services Market: Regional Estimates & Trend Analysis
Chapter 6. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Boehringer Ingelheim International GmbH
- Fresenius Kabi AG
- Unither Pharmaceuticals
- Lonza
- Pfizer Inc.
- Charles River Laboratories
- Laboratory Corporation of America Holdings
- IQVIA, Inc.
- Recipharm AB.
- AbbVie, Inc.
- Catalent, Inc.
- West Pharmaceutical Services, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | April 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 20.2 Billion |
| Forecasted Market Value ( USD | $ 37.2 Billion |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | Latin America |
| No. of Companies Mentioned | 12 |
